Stock Market Reviews

COGT (Cogent Biosciences, Inc.) News

Get the latest news, insights, and market updates on COGT (Cogent Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
  Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.
  Feb 17, 2026 - $COGT
• Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
  This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
  Feb 17, 2026 - $COGT
• Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
  SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026PEAK NDA initiated for bezuclastinib in patients with 2L GIST under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD); completion of NDA on track for April 2026Six abstracts from SUMMIT trial of bezuclastinib in patients with NonAdvSM accepted for presentation at 2026 AAAAI annual meetingStrong financial posi
  Feb 17, 2026 - $COGT
• Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
  WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced multiple upcoming posters highlighting bezuclastinib results from the SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients at the 2026 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in Philadelphia, PA, February 27-March 2
  Feb 10, 2026 - $COGT
• Cogent Biosciences FDA Milestones Put Bezuclastinib And Valuation In Focus
  Cogent Biosciences received FDA Breakthrough Therapy Designation for bezuclastinib in combination with sunitinib in gastrointestinal stromal tumors (GIST). The FDA also accepted Cogent’s New Drug Application for bezuclastinib into the Real-Time Oncology Review program. These regulatory updates highlight potential changes for future treatment options in GIST if the drug is ultimately approved. Cogent Biosciences, traded as NasdaqGS:COGT, is drawing fresh attention with these back to back...
  Feb 2, 2026 - $COGT
• Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD)
  Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the 11 Best Performing Stocks in the Last 12 Months. On January 26, 2026, Cogent Biosciences, Inc. (NASDAQ:COGT) announced a major milestone, receiving a Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration. The designation came for bezuclastinib in combination with sunitinib for patients with Gastrointestinal […]
  Feb 2, 2026 - $COGT
• Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M
  A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual performance ever in 2025.
  Feb 1, 2026 - $COGT
• Elastic NV, Acadia Healthcare, and More Stocks See Action From Activist Investors
  13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
  Jan 31, 2026 - $COGT
• Cogent Biosciences announcse U.S. BTD for bezuclastinib
  Cogent Biosciences (COGT) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation, BTD, for bezuclastinib in combination with sunitinib for patients with Gastrointestinal Stromal Tumors who have received prior treatment with imatinib. “We are excited to announce this Breakthrough Therapy Designation which recognizes the potential for the bezuclastinib combination to substantially improve upon the currently available treatment options for patients with im
  Jan 27, 2026 - $COGT
• Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
  - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for bezuclastinib in c
  Jan 26, 2026 - $COGT